NCT04190550View on ClinicalTrials.gov

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Interventions
DRUG

Cytarabine

Given IV

DRUG

Idarubicin Hydrochloride

Given IV

DRUG

Navtemadlin

Given PO

Trial Locations (6)

10016

Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

60611

Northwestern University, Chicago

73104

University of Oklahoma Health Sciences Center, Oklahoma City

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH